The overall objective of the Viral Vector and Transgenic Mouse Core is to provide Diabetes Research Center affiliate investigators at the University of Washington with state-of-the-art vectors necessary to overexpress, knockdown, knockout, or otherwise alter expression of RNAs and proteins of interest in cultured cells, isolated fissues, and animals. The Core has considerably evolved since the last competifive renewal. New services to generate genetically engineered mice have been added, and under-ufilized and standard molecular biology methods that are now increasingly performed in individual investigator's labs have been removed.
The specific aims of the Core are to provide the following services to affiliate invesfigators: (1) Producfion of lentiviral, adenoviral and retroviral vectors for use in animals, fissues, and cells;(2) Producfion of vectors for generation of transgenic, knockout, and knockin mice;(3) Specialized molecular biology methods not routinely performed in affiliate investigators'laboratories;(4) Cost-effective production of genefically engineered mice through the University of Washington Transgenic Resources Program;and (5) Consultafion and training.. The Core has been highly productive in the current funding period and has added new services that are expected to significantly increase producfivity and usability for Diabetes Research Center affiliate investigators to meet the Center's goal to enhance research in diabetes, obesity and related disorders in the Greater Seattle area and beyond.

Public Health Relevance

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK017047-37
Application #
8440620
Study Section
Special Emphasis Panel (ZDK1-GRB-S (O2))
Project Start
Project End
Budget Start
2013-03-13
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$170,877
Indirect Cost
$72,341
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Houston, Denise K; Neiberg, Rebecca H; Miller, Michael E et al. (2018) Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. J Gerontol A Biol Sci Med Sci 73:1552-1559
Guo, Rui; Hua, Yinan; Ren, Jun et al. (2018) Cardiomyocyte-specific disruption of Cathepsin K protects against doxorubicin-induced cardiotoxicity. Cell Death Dis 9:692
van Zuydam, Natalie R; Ahlqvist, Emma; Sandholm, Niina et al. (2018) A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes 67:1414-1427
Tanaka, Shigeru; Pfleger, Christian; Lai, Jen-Feng et al. (2018) KAP1 Regulates Regulatory T Cell Function and Proliferation in Both Foxp3-Dependent and -Independent Manners. Cell Rep 23:796-807
Koletzko, Sibylle; Lee, Hye-Seung; Beyerlein, Andreas et al. (2018) Cesarean Section on the Risk of Celiac Disease in the Offspring: The Teddy Study. J Pediatr Gastroenterol Nutr 66:417-424
Roe, Nathan D; Handzlik, Michal K; Li, Tao et al. (2018) The Role of Diacylglycerol Acyltransferase (DGAT) 1 and 2 in Cardiac Metabolism and Function. Sci Rep 8:4983
Chepurny, Oleg G; Bonaccorso, Ron L; Leech, Colin A et al. (2018) Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors. Sci Rep 8:3749
Hull, Rebecca L; Gibson, Ronald L; McNamara, Sharon et al. (2018) Islet Interleukin-1? Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to ?-Cell Failure. Diabetes Care 41:823-830
Kikuchi, Shinsuke; Chen, Lihua; Xiong, Kevin et al. (2018) Smooth muscle cells of human veins show an increased response to injury at valve sites. J Vasc Surg 67:1556-1570.e9
Erickson, Michelle A; Banks, William A (2018) Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions. Pharmacol Rev 70:278-314

Showing the most recent 10 out of 1296 publications